Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

SAB World of Learning Brewery bid awarded to Kovsie Brewing
2017-11-28

Description: Kovsie Brewing 2 2017 Tags: Kovsie Brewing 2 2017 

Visitors from SA Breweries (AB InBev), Khosi Mogotsi,
Patience Selesho and Zinhle Ngcobo with
Dr Jan-G Vermeulen and Dr Errol Cason from
Kovsie Brewery.
Photos: Moeketsi Mogotsi

With the recent procurement of SAB by Anheuser-Busch InBev SA/NV (AB InBev), a Belgian transnational beverage and brewing company, the 500L educational brewery located at the SAB Cyril Ramaphosa World of Learning, became available for donation. After an initial shortlisting of three universities, the SAB World of Learning Brewery was awarded to the University of the Free State (UFS) to be managed by Kovsie Brewing.

Prof Corli Witthuhn, Vice-Rector: Research at the UFS, approved the application for a micro-manufacturing liquor licence right in the middle of campus, which effectively put the UFS bid in a class of its own. It is part of her vision that entrepreneurial activities must be visible on campus”

Sixteen universities were approached to obtain the brewery for their respective campuses.

Kovsie Brewing is an initiative started by postgraduate students at the UFS Department of Microbial, Biochemical and Food Biotechnology in 2012. The main objective of this initiative was to expose BSc students to brewing as a practical application of the scientific fields presented at the department.
 

Description: Kovsie Brewing 1 2017 Tags: Kovsie Brewing 1 2017 

Label mock-ups made by
Dr Jan-G Vermeulen from
Kovsie Brewery entered into
the yearly  SAB Intervarsity
Brewing Competition. Kovsie
Brewing has won the best label
competition in 2013, 2014 and 2015
and was placed in the top three in
2016 and 2017.


First brewing and fermentation school
Dr Errol Cason, project leader at Kovsie Brewery, said: “Over the past five years the small-scale experimental brewery has steadily grown to the point where we obtained institutional support to establish the first Brewing and Fermentation School at the university.

Dr Cason explains that the primary role of Kovsie Brewing is to establish an accredited fermentation-based curriculum at the UFS to educate undergraduate and postgraduate students in the scientific process involved in the production of beer. “In addition, the donation enables Kovsie Brewing to provide practical job-related training and skills development on industrial grade equipment,” he said.

Emphasis on entrepreneurship
The secondary role is for Kovsie Brewing to function as a multi-disciplinary platform to stimulate the interaction between students from various fields of study. Currently Kovsie Brewing has well-established cooperative projects with both Marketing and Entrepreneurship programmes.

“In the future, Kovsie Brewing will expand on these multi-disciplinary interactions by incorporating other departments of the UFS with the focus on product development, logistics, as well as the legal aspects concerned with brewing,” Dr Jan-G Vermeulen from the Kovsie Brewery team said.

Corporate social investment representatives from AB InBev recently visited the university. Among others they met Drs Vermeulen and Cason. During their visit they also looked at other university projects, including the Department of Paediatric and Child Health and the Universitas Hospital, the Engineering Sciences Department and the Naval Hill Planetarium.

Khosi Mogotsi from AB InBev said: “It was wonderful to experience the passion with which UFS staff do their work.”

 

 

 

 

 

 

 

 

 

 

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept